NO151364B - Analogifremgangsmaate for fremstilling av terapeutisk aktive n-substituerte heterocykliske forbindelser - Google Patents
Analogifremgangsmaate for fremstilling av terapeutisk aktive n-substituerte heterocykliske forbindelser Download PDFInfo
- Publication number
- NO151364B NO151364B NO792485A NO792485A NO151364B NO 151364 B NO151364 B NO 151364B NO 792485 A NO792485 A NO 792485A NO 792485 A NO792485 A NO 792485A NO 151364 B NO151364 B NO 151364B
- Authority
- NO
- Norway
- Prior art keywords
- optionally
- compounds
- alkyl
- general formula
- hydrogenolytically
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 11
- 238000002360 preparation method Methods 0.000 title claims description 7
- 230000001225 therapeutic effect Effects 0.000 title claims description 3
- 150000001421 N-substituted heterocyclic compounds Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 44
- 239000002253 acid Substances 0.000 claims abstract description 7
- 150000003839 salts Chemical class 0.000 claims abstract 6
- 229910052736 halogen Inorganic materials 0.000 claims abstract 4
- 150000002367 halogens Chemical class 0.000 claims abstract 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims abstract 3
- 125000002252 acyl group Chemical group 0.000 claims abstract 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims abstract 2
- 229910052760 oxygen Inorganic materials 0.000 claims abstract 2
- 239000001301 oxygen Substances 0.000 claims abstract 2
- 239000003054 catalyst Substances 0.000 claims description 14
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- 125000006239 protecting group Chemical group 0.000 claims description 9
- 239000001257 hydrogen Substances 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 7
- 230000002829 reductive effect Effects 0.000 claims description 6
- 150000001412 amines Chemical class 0.000 claims description 5
- 238000005984 hydrogenation reaction Methods 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 150000004678 hydrides Chemical class 0.000 claims description 4
- 150000002431 hydrogen Chemical class 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 claims description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 150000002373 hemiacetals Chemical class 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- OJUGVDODNPJEEC-UHFFFAOYSA-N phenylglyoxal Chemical compound O=CC(=O)C1=CC=CC=C1 OJUGVDODNPJEEC-UHFFFAOYSA-N 0.000 claims 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 230000001603 reducing effect Effects 0.000 claims 1
- 238000006722 reduction reaction Methods 0.000 claims 1
- 238000006268 reductive amination reaction Methods 0.000 claims 1
- -1 R3 is H Chemical class 0.000 abstract description 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract description 4
- 230000003266 anti-allergic effect Effects 0.000 abstract description 3
- 230000002048 spasmolytic effect Effects 0.000 abstract description 3
- 239000000043 antiallergic agent Substances 0.000 abstract description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 208000001953 Hypotension Diseases 0.000 abstract 1
- 230000000572 bronchospasmolytic effect Effects 0.000 abstract 1
- 208000021822 hypotensive Diseases 0.000 abstract 1
- 230000001077 hypotensive effect Effects 0.000 abstract 1
- 229940035363 muscle relaxants Drugs 0.000 abstract 1
- 239000003158 myorelaxant agent Substances 0.000 abstract 1
- 231100000252 nontoxic Toxicity 0.000 abstract 1
- 230000003000 nontoxic effect Effects 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 39
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- 239000012279 sodium borohydride Substances 0.000 description 9
- 229910000033 sodium borohydride Inorganic materials 0.000 description 9
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 8
- 239000000155 melt Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 229910052763 palladium Inorganic materials 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 6
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 125000000623 heterocyclic group Chemical group 0.000 description 5
- 206010046763 Uterine atony Diseases 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- 230000001813 broncholytic effect Effects 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- MVNLUVUWXYAIBP-UHFFFAOYSA-N 4-(benzimidazol-1-yl)-2-methylbutan-2-amine Chemical compound C1=CC=C2N(CCC(C)(N)C)C=NC2=C1 MVNLUVUWXYAIBP-UHFFFAOYSA-N 0.000 description 3
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 239000007868 Raney catalyst Substances 0.000 description 3
- 229910000564 Raney nickel Inorganic materials 0.000 description 3
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 229940124630 bronchodilator Drugs 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 239000012452 mother liquor Substances 0.000 description 3
- 235000006408 oxalic acid Nutrition 0.000 description 3
- 229910052697 platinum Inorganic materials 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 239000002249 anxiolytic agent Substances 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 229960001022 fenoterol Drugs 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 2
- GKKCIDNWFBPDBW-UHFFFAOYSA-M potassium cyanate Chemical compound [K]OC#N GKKCIDNWFBPDBW-UHFFFAOYSA-M 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- JPJALAQPGMAKDF-UHFFFAOYSA-N selenium dioxide Chemical compound O=[Se]=O JPJALAQPGMAKDF-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- MBEYZAPSDJKKFV-UHFFFAOYSA-N 1-(1h-benzimidazol-2-yl)propan-1-amine Chemical compound C1=CC=C2NC(C(N)CC)=NC2=C1 MBEYZAPSDJKKFV-UHFFFAOYSA-N 0.000 description 1
- KIRDUVUAZUJAHC-UHFFFAOYSA-N 1-(3-amino-4-phenylmethoxyphenyl)-2-[(4-imidazol-1-yl-2-methylbutan-2-yl)amino]ethanol Chemical compound C=1C=C(OCC=2C=CC=CC=2)C(N)=CC=1C(O)CNC(C)(C)CCN1C=CN=C1 KIRDUVUAZUJAHC-UHFFFAOYSA-N 0.000 description 1
- HWYCEKIUTFYHKV-UHFFFAOYSA-N 1-[3-(hydroxymethyl)-4-phenylmethoxyphenyl]-2-[(4-imidazol-1-yl-2-methylbutan-2-yl)amino]ethanol Chemical compound C=1C=C(OCC=2C=CC=CC=2)C(CO)=CC=1C(O)CNC(C)(C)CCN1C=CN=C1 HWYCEKIUTFYHKV-UHFFFAOYSA-N 0.000 description 1
- VYPLFXSPDSTKHW-UHFFFAOYSA-N 1-[3-[[2-hydroxy-2-(4-hydroxyphenyl)ethyl]amino]propyl]-2,3-dihydroquinazolin-4-one Chemical compound C1NC(=O)C2=CC=CC=C2N1CCCNCC(O)C1=CC=C(O)C=C1 VYPLFXSPDSTKHW-UHFFFAOYSA-N 0.000 description 1
- DZPYWSKFSVKUCV-UHFFFAOYSA-N 2-(2,5-dichloro-4-hydroxyphenyl)-2-oxoacetaldehyde;hydrate Chemical compound O.OC1=CC(Cl)=C(C(=O)C=O)C=C1Cl DZPYWSKFSVKUCV-UHFFFAOYSA-N 0.000 description 1
- PPSLHCIXAUOVMK-UHFFFAOYSA-N 2-[3-(benzimidazol-1-yl)propylamino]-1-(4-phenylmethoxyphenyl)ethanol Chemical compound C1=NC2=CC=CC=C2N1CCCNCC(O)C(C=C1)=CC=C1OCC1=CC=CC=C1 PPSLHCIXAUOVMK-UHFFFAOYSA-N 0.000 description 1
- HKZCTVKEUUJGLY-UHFFFAOYSA-N 2-[[4-(benzimidazol-1-yl)-2-methylbutan-2-yl]amino]-1-(2-fluoro-4-phenylmethoxyphenyl)ethanol;oxalic acid Chemical compound OC(=O)C(O)=O.OC(=O)C(O)=O.C1=NC2=CC=CC=C2N1CCC(C)(C)NCC(O)C(C(=C1)F)=CC=C1OCC1=CC=CC=C1 HKZCTVKEUUJGLY-UHFFFAOYSA-N 0.000 description 1
- IAPCKPXQFYWNDN-UHFFFAOYSA-N 2-bromo-1-(4-phenylmethoxyphenyl)ethanone Chemical compound C1=CC(C(=O)CBr)=CC=C1OCC1=CC=CC=C1 IAPCKPXQFYWNDN-UHFFFAOYSA-N 0.000 description 1
- DJMUZABCMFQZBA-UHFFFAOYSA-N 2-ethoxy-1-(2-fluoro-4-phenylmethoxyphenyl)-2-hydroxyethanone Chemical compound C1=C(F)C(C(=O)C(O)OCC)=CC=C1OCC1=CC=CC=C1 DJMUZABCMFQZBA-UHFFFAOYSA-N 0.000 description 1
- FUXNMQXIGSVTJV-UHFFFAOYSA-N 2-hydroxy-5-[1-hydroxy-2-[(4-imidazol-1-yl-2-methylbutan-2-yl)amino]ethyl]-n-methylbenzamide;sulfuric acid Chemical compound OS(O)(=O)=O.C1=C(O)C(C(=O)NC)=CC(C(O)CNC(C)(C)CCN2C=NC=C2)=C1 FUXNMQXIGSVTJV-UHFFFAOYSA-N 0.000 description 1
- LEPOAPIKIGRMLR-UHFFFAOYSA-N 3-(2-bromoacetyl)-6-hydroxy-6-phenylmethoxycyclohexa-2,4-diene-1-carboxamide Chemical compound NC(=O)C1C=C(C(=O)CBr)C=CC1(O)OCC1=CC=CC=C1 LEPOAPIKIGRMLR-UHFFFAOYSA-N 0.000 description 1
- YTTOVIWXZJVEQO-UHFFFAOYSA-N 3-(benzotriazol-1-yl)propan-1-amine Chemical compound C1=CC=C2N(CCCN)N=NC2=C1 YTTOVIWXZJVEQO-UHFFFAOYSA-N 0.000 description 1
- NKNUZEDNCHLYSV-UHFFFAOYSA-N 4-[2-[3-(benzimidazol-1-yl)propylamino]-1-hydroxyethyl]phenol Chemical compound C1=NC2=CC=CC=C2N1CCCNCC(O)C1=CC=C(O)C=C1 NKNUZEDNCHLYSV-UHFFFAOYSA-N 0.000 description 1
- KOTMQCNDGLTIHR-UHFFFAOYSA-N 4-[2-[[4-(benzimidazol-1-yl)-2-methylbutan-2-yl]amino]-1-hydroxyethyl]-3-fluorophenol Chemical compound C1=NC2=CC=CC=C2N1CCC(C)(C)NCC(O)C1=CC=C(O)C=C1F KOTMQCNDGLTIHR-UHFFFAOYSA-N 0.000 description 1
- VXWSXLSUWGZOHD-UHFFFAOYSA-N 5-(2-bromoacetyl)-2-hydroxybenzamide Chemical compound NC(=O)C1=CC(C(=O)CBr)=CC=C1O VXWSXLSUWGZOHD-UHFFFAOYSA-N 0.000 description 1
- 229930008281 A03AD01 - Papaverine Natural products 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 208000009079 Bronchial Spasm Diseases 0.000 description 1
- 208000014181 Bronchial disease Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- OMGXNULMTYGOMY-UHFFFAOYSA-N C1NC(=O)C2=CC=CC=C2N1CCCNCCCC3C=CC=CC3(C4=CC=C(C=C4)OCC5=CC=CC=C5)O Chemical compound C1NC(=O)C2=CC=CC=C2N1CCCNCCCC3C=CC=CC3(C4=CC=C(C=C4)OCC5=CC=CC=C5)O OMGXNULMTYGOMY-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 229960001413 acetanilide Drugs 0.000 description 1
- 150000008062 acetophenones Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- 229940073608 benzyl chloride Drugs 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- OJGDCBLYJGHCIH-UHFFFAOYSA-N bromhexine Chemical compound C1CCCCC1N(C)CC1=CC(Br)=CC(Br)=C1N OJGDCBLYJGHCIH-UHFFFAOYSA-N 0.000 description 1
- 229960003870 bromhexine Drugs 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- MOIPGXQKZSZOQX-UHFFFAOYSA-N carbonyl bromide Chemical class BrC(Br)=O MOIPGXQKZSZOQX-UHFFFAOYSA-N 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000003086 effect on acetylcholine Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 229960001361 ipratropium bromide Drugs 0.000 description 1
- KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 230000003170 musculotropic effect Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000000754 myometrium Anatomy 0.000 description 1
- LBTPIFQNEKOAIM-UHFFFAOYSA-N n-phenylmethanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC=C1 LBTPIFQNEKOAIM-UHFFFAOYSA-N 0.000 description 1
- FWFGVMYFCODZRD-UHFFFAOYSA-N oxidanium;hydrogen sulfate Chemical compound O.OS(O)(=O)=O FWFGVMYFCODZRD-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229960001789 papaverine Drugs 0.000 description 1
- 230000002445 parasympatholytic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- WVSZBAHKLHXQFN-UHFFFAOYSA-N tetrahydrate;dihydrochloride Chemical compound O.O.O.O.Cl.Cl WVSZBAHKLHXQFN-UHFFFAOYSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/30—Oxygen or sulfur atoms
- C07D233/32—One oxygen atom
- C07D233/36—One oxygen atom with hydrocarbon radicals, substituted by nitrogen atoms, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
- C07D239/96—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
- C07D249/18—Benzotriazoles
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Photoreceptors In Electrophotography (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
Denne oppfinnelse angår en fremgangsmåte for fremstilling av nye terapeutisk aktive forbindelser slik som definert i kravene.
Ved fremgangsmåte a) anvendes oppløsningsmidler som
under reaksjonsbetingelsene er tilstrekkelig inerte, f.eks. alkoholer så som metanol og etanol, og vanlige hydrogeneringskatalysatorer som f.eks. palladium, platina og Raney-nikkel. Hydrider som kan anvendes som reduksjonsmiddel, er natriumborhydrid og andre komplekse hydrider, eller diboran. Reaksjons-temperaturen ligger mellom ca. 0°C og reaksjonsblandingens koketemperatur. Hvis den sentrale (i sidekjeden) aminogruppe eller substituentene R 10 og/eller R2 i utgangsmaterialet inneholder en hydrogenolytisk avspaltbar beskyttelsesgruppe,
f.eks. en eventuelt substituert benzylgruppe, fjernes denne under eller om nødvendig efter reduksjonen av CO-gruppen.
Utgangsmaterialene med formel II får man f.eks. ved omsetning av aminer III med bromketoner IV i slike oppløsningsmidler som acetontril eller etylacetat i nærvær av et syreoppfangende middel så som natriumkarbonat eller aminoverskudd:
Forbindelser med formel I er ikke tidligere beskrevet.
I Tysk offentliggjørelsesskrift 1 643 224 er det riktignok angitt en generell formel hvor alkylgruppen R^ som er bundet til nitrogenatomet i sidekjeden/ kan være substituert med heterocykliske ringer med minst ett heteroatom. Arten av de heterocykliske ringer er imidlertid ikke nærmere definert, og som eksempel er bare angitt en morfolinogruppe. Det finnes ingen henvisning til de hovedsaklig dicykliske heterocykliske grupper som det er tale om ifølge fore-liggende oppfinnelse. Av forbindelsene som er kjent fra dette offentliggjørelsesskrift, er et N-tert.^butylderivat (Salbutamol) i handelen som bronkolytisk middel. De nye forbindelser fremstilt ifølge oppfinnelsen har ved forsøk vist seg å være bedre enn dette kjente produkt.
Tysk offentliggjørelsesskrift 2 238 504 angår beslektede forbindelser med /3-blokkerende virkning. De oppviser 1-fenoksy-2-ol-3-amino-strukturen som er typisk for mange Ø-blokkere. Forbindelsene fremstilt ifølge oppfinnelsen oppviser imidlertid en Ø-mimetisk virkning. En overføring av struktur/virkningsforholdet fra offentliggjørelsesskriftet til de nye forbindelser fremstilt ifølge oppfinnelsen er således ikke mulig.
I tysk offentliggjørelsesskrift 2 135 678 er det nevnt forbindelser som istedenfor den heterocykliske rest i de nye forbindelser med formel I inneholder en substituert fenylring. Det er ikke noe holdepunkt for at en slik fenylrest skulle være ekvivalent med en heterocyklisk rest.
R^' betyr R^ eller en hydrogenolytisk avspaltbar rest så som benzyl, R<1> betyr H eller en hydrogenolytisk avspaltbar rest så som benzyl, og de øvrige symboler er som ovenfor definert.
Ved fremgangsmåte b) kan forbindelsen med formel VI også anvendes i form av et halvacetal, dvs. i form av forbindelser med formelen
hvor R^, R2 og R^ har de ovenfor angitte betydninger, og alkyl betyr en eventuelt substituert alkylrest fortrinnsvis inneholdende 1-6 karbonatomer.
De Schiffske baser VII, som eventuelt opptrer som mellomprodukter:
hvor de enkelte symboler er som ovenfor angitt, kan også isoleres og derefter underkastes reduksjon.
Som reduksjonsmiddel anvendes komplekse hydrider, fortrinnsvis natriumborhydrid, eller hydrogen i nærvær av hydrogeneringskatalysatorer så som platina, palladium eller Raney-nikkel. Hvis R^O og/eller R2 betyr fenoliske OH-grupper
som foreligger beskyttet med en hydrogenolytisk avspaltbar gruppe, f.eks. benzyl, fjernes disse grupper hvis nødvendig efter reduksjonen på vanlig måte.
Aminene med formel IV kan f.eks. fremstilles ved at de heterocykliske forbindelser Het-H alkyleres på aminogruppen med forbindelser med formel X:
hvor R,., Rg og n har de ovenfor angitte betydninger,
X betyr klor, brom eller en metyl- eller tolylsulfonsyrerest, og B betyr en funksjonell gruppe så som N02, dibenzylamino eller benzalamino, som ved katalytisk hydrogenering eller hydrolyse kan omdannes til en aminogruppe, i nærvær av natrium-hydrid i oppløsningsmidler så som heksametylfosforsyretriamid, og derefter overføres den funksjonelle rest B til aminogruppen.
Fenylglyoksalene VI resp. de tilsvarende halv-acetaler som anvendes som utgangsmaterialer, kan f.eks. fremstilles ved oksydasjon av acetofenonene IX:
hvor R^, R2 og R3 er som ovenfor angitt, med selendioksyd i vandig dioksan og krystallisasjon fra vann eller alkoholer.
Ved fremgangsmåte c) skjer avspaltningen av beskyttelses-gruppene med hydrogen og hydrogeneringskatalysatorer så som palladium, platina eller Raney-nikkel ved temperaturer mellom 0°C og reaksjonsblandingens koketemperatur. Som oppløsningsmidler anvendes fortrinnsvis lavere alkoholer, særlig metanol.
Utgangsmaterialene XI kan fremstilles i henhold til fremgangsmåtene a) eller b). En annen mulighet består i at de forbindelser med formel XII:
hvor n, Het, R', R^' og R^ til Rg har de ovenfor angitte betydninger, og R2" betyr forstadier for R2' lik NH-CONH-Rg, NHCORg, NHS02R7, NH-CH2-C6H4-Rg (f .eks. NH2) eller lik
CH2OH, CONHRg (f.eks. COOC2H5), omvandles forstadiene til de tilsvarende grupper R2<1> ved vanlige metoder.
Således kan man fra forbindelser med formel XII hvor R2" er NH2, med kaliumcyanat fremstille forbindelser med
formel XI med R2<1> lik NHCONH2 eller med (RgCO)20 forbindelsene med R ' lik NH-CORQ. Forbindelser med R " lik COOC_Hc gir ved reduksjon med litiumaluminiumhydrid forbindelser med formel XI med R2<1> lik CH2OH, ved omsetning med aminer H,,NRg forbindelser med formel XI med R2<1> lik CONHRg.
De nye forbindelser kan anvendes som legemidler.
De har særlig bronkolytisk, spasmolytisk og antiallergisk virkning og kan således anvendes ved behandling av bronkitt og astma, ved neslefeber, konjunktivitt, høyfeber og forkjølelses-sykdommer, og dessuten som relakserende midler for livmor-muskulaturen, f.eks. ved problemer før fødsel. Dessuten er de nye forbindelser egnet til behandling av kardiovaskulære forstyrrelser, så som forhøyet blodtrykk, perifere karsykdommer og hjertearytmier.
Dessuten kan nevnes den hemmende virkning på mave-sekresjonen og den - spesielt antidepressive - virkning på sentralnervesystemet.
Her skal fremheves den sterke og langvarige bronkolytiske virkning som bare er forbundet med liten bivirkning på hjerte og skjelettmuskulaturen.
Forbindelsene med formel I med R2 lik CONHRg virker blodtrykksenkende, mens de øvrige forbindelser har de andre angitte virkninger.
Den terapeutiske dose er avhengig av den anvendte forbindelse, arten av sykdomstilstanden, administreringsformen og også kroppsvekten, hvis ikke en lokal anvendelse benyttes.
For voksne kommer følgende dosering pr. dag i betraktning: Til bronkolyse, oralt 2-20 mg, inhalativt 0,1-1,5 mg,
subkutant 0,2-1,5 mg. Til uterusspasmolyse: oralt 10-50 mg, som infusjonsløsning 0,1-1 mg i ampuller med 10 ml løsning.
For karutvidelse kan man gi oralt 20-100 mg, i form av løsninger for intramuskulær injeksjon 20-40 mg, til blodtrykksenkning oralt 200-1800 mg.
For preparatfremstilling fremstilles av de nye forbindelser de vanlige galeniske preparater, f.eks. kapsler,
tabletter, dragéer, oppløsninger, suspensjoner, pulvere, kremer, salver, emulsjoner eller spraypreparater. For pulmonal administrering bringes fortrinnsvis pulver med en partikkel-størrelse 0,5 til 7 ym som aerosol med pusteluften, eventuelt også med ytterligere drivgasser, til bronkialområdet.
Den parenterale anvendelse skjer fortrinnsvis i form av sterile, isotoniske, vandige oppløsninger, mens det for lokal anvendelse særlig anvendes losjoner, kremer, salver, emulsjoner og spraypreparater.
De gunstige virkningsforhold for de nye forbindelser illustreres ved hjelp av de følgende data.
1. Bronkospasmolyse
Virkningen ble undersøkt på marsvin i uretan-narkose. Ved hjelp av kroppsplethysmografi ble innvirkningen på acetyl-cholin-bronkospasme bestemt efter intravenøs og oral administrering. Dessuten ble hjertefrekvensen kontrollert.
De nye forbindelser viser et utmerket forhold mellom intravenøs og oral virkning. Innvirkningen på hjertefrekvensen er samtidig liten. Dessuten er toksisiteten så lav at de har en betydelig terapeutisk bredde. F.eks. er for forbindelsen ifølge eksempel 6 LD5Q på mus i.v. 29 mg/kg, p.o. 330 mg/kg.
2. Livmoravspenning
Livmoravspenningen ble undersøkt på narkotiserte rotter. Man bestemte den intravenøse ED,-q for livmoravspenningen i pg/kg (50% av de undersøkte dyr reagerer) og dessuten den (uønskede) økning av hjertefrekvensen ved ED^Q-verdien. Sammenligningsforbindelse er fenoterol
Forbindelsene fremstilt ifølge oppfinnelsen bevirker således ved administrering av ED^q for livmoravspenning en betydelig lavere økning i hjertefrekvensen enn handelsproduktet fenoterol.
De nye forbindelser kan også anvendes i kombinasjon
med kjente aktivstoffer; for bronkolytisk anvendelse f.eks. sammen med teofylliner, parasympatolytika (f.eks. ipratropium-bromid), sekretolytika (f.eks. bromheksin), muskulotrope spasmolytika (f.eks. papaverin), kortikosteroider,og anti-allergika. Når det gjelder de livmoravspennende midler, er bl.a. kombinasjoner med kortikoider mulig.
Oppfinnelsen skal illustreres nærmere i de følgende eksempler. Utbytteangivelsene i tabellene er % av det teoretiske.
Til fremgangsmåte 1
Eksempel 1
30,5 g 2-brom-p-benzyloksyacetofenon og 35 g 1-amino-propylbenzimidazol omrøres i 150 ml acetonitril i 1 time ved 30-40°C. Efter fraskillelse av hydrobromidet surgjøres moderluten med 12 g maleinsyre, og det utfelte a-[3-(1-benzimidazolyl)-propyl-amino]-4-benzyloksyacetofenon-maleinat (sm.p. 145-148°C) avsuges. Med vandig ammoniakk fremstilles derefter basen som reduseres med natriumborhydrid i 200 ml alkohol til 1-(4-benzyloksy-fenyl)-2-[3-(1-benzimidazolyl)-propylamino]-etanol (sm.p. 83-85°C).
Ved katalytisk hydrogenering av 7 g av denne forbindelse
i 100 ml metanol med 1 g palladiumkull som katalysator får man 4,5 g 1-(4-hydroksyfenyl)-2-[3-(1-benzimidazolyl)-propylamino]-etanol (sm.p. 146-148°C, utbytte 83% av det teoretiske), hvis dihydroklorid smelter ved 184-185°C.
Eksempel 2
17,5 g 2-benzyloksy-5-bromacetyl-salicylamid, 17,6 g 1-(3-aminopropyl)-lH-benztriazol, 6 g natriumkarbonat og 150 ml etylacetat tilbakeløpsbehandles i 1,5 timer. Efter fraskillelse av de uorganiske bestanddeler inndampes moderluten, residuet oppløses i 100 ml acetonitril og surgjøres med 5 g oksalsyre. Det utfelte 1-[3- (3-karbamoyl-4-benzyloksy-8-okso-fenetylamino)-propyl]-1-H-benztriazol-oksalat avsuges, overføres med vandig ammoniakk til basen (sm.p. 186-188°C) og reduseres i 100 ml etanol med natriumborhydrid til 1- (3-karbamoyl-4-benzyloksy-6-hydroksyfenetylamino)-propyl]-1-H-benztriazol.
Ved hydrogenering av 6 g av denne forbindelse i 100 ml metanol ved 6 bar trykk og 40°C under tilsetning av palladiumkull får man 3 g 1-[3-(3-karbamoyl-4,B-dihydroksyfenetylamino)-propyl]-1-H-benztriazol (sm.p. 154-155°C, utbytte 77,5% av det teoretiske), hvis cyklamat smelter ved 16 5°C.
Eksempel 3
12,9 g 5-bromacetylsalicylamid, 15,45 g l-(3-benzyl-aminopropyl)-3-metyl-kinazolin-2,4-dion, 6 g natriumkarbonat og 300 ml acetonitril kokes i 1,5 timer under tilbakeløps-kjøling. Efter avsugning av de uorganiske bestanddeler inndampes moderluten, residuet oppløses i 500 ml metanol og hydrogeneres efter tilsetning av 12 ml benzylklorid ved 6 bar og 60°C med palladiumkull som katalysator. Efter opptagelse av 2 mol hydrogen opparbeides reaksjonsblandingen, og det dannede l-[3-(3-karbamoyl-3-okso-4-hydroksyfenetylamino)-propyl]-3-metyl-kinazolin-2,4-dion-hydroklorid (sm.p. = 253°C, spaltn.) isoleres.
Ved katalytisk hydrogenering av 13 g av denne forbindelse i 250 ml metanol/vannblanding 1:1 ved 6 bar trykk, 50°C med palladium som katalysator, får man 8 g 1- [ 3-karbamoyl-4-B-dihydroksyfenetylamino)-propyl]-3-metyl-kinazolin-2,4-dion-hydroklorid hvis smeltepunkt er 220-221°C. Utbytte: 61,5% av det teoretiske.
Til fremgangsmåte 2 Eksempel 4
9,3 g 2,5-diklor-4-hydroksyfenylglyoksalhydrat,
7,25 g 1-(3-amino-3-metyl-butyl)benzimidazol og 100 ml alkohol omrøres i 3 timer ved 40-50°C. Derefter avkjøles oppløsningen, tilsettes porsjonsvis 8 g natriumborhydrid og omrøres i 3 timer ved romtemperatur. Efter tilsetning av 100 ml metanol for spaltning av natriumborhydridet får reaksjonsblandingen stå i 10 timer, oppløsningsmidlet avdestilleres under redusert trykk,
residuet oppløses i 200 ml vann og surgjøres med kons. saltsyre. Det isoleres 9,5 g 1-(2,5-diklor-4-hydrofenyl)-2-[4-(1-benz-imidazolyl )-2-metyl-2-butylamino]-etanol-dihydroklorid x 1 vann som smelter ved 180-183°C. Utbyttet er 50,4% av det teoretiske.
Eksempel 5
14,4 g 21-benzyloksy-51 -(l-okso-2-hydroksy-2-etoksy-etyl)-metansulfonanilid, 7 g 1-(3-amino-3-metyl-butyl)-benzimidazol og 150 ml alkohol oppvarmes i 3 timer til 50°C og tilsettes porsjonsvis 9,2 g natriumborhydrid. Oppløsningen holdes i 12 timer ved romtemperatur, derefter fjernes alkoholen under redusert trykk på en såkalt Rotavapor, og residuet oppløses med 200 ml vann og 500 ml etylacetat. Efter spaltning av natriumborhydridet under omrøring med kons. saltsyre under isavkjøling gjøres reaksjonsblandingen alkalisk med ammoniakk, etylacetat-fasen fraskilles, tørres med natriumsulfat og inndampes på Rotavapor.
Residuet oppløses i 200 ml alkohol, surgjøres med 6,3 g oksalsyre, og det utfelte 2<1->benzyloksy-5'-[l-hydroksy-2-[4-(1-benzimidazolyl)-2-metyl-2-butylamino]etyl]-metansulfonanilid-dioksalat (sm.p. 185-187°C) avsuges. Fra denne forbindelse fremstilles basen (sm.p. 65-70°C) med vandig ammoniakk. Ved katalytisk hydrogenering av denne forbindelse (sm.p. 65-70°C) i 250 ml metanol under normalbetingelser med palladiumkull som katalysator får man 8 g 2'-hydroksy-51 -[l-hydroksy-2-[4-(1-benzimidazolyl)-2-metyl-2-butylamino]-etyl]-metansulfonanilid (sm.p. 170-173°C, utbytte 81% av det teoretiske), hvis formiat smelter ved 161-164°C.
Eksempel 6
15,2 g 1-(2-fluor-4-benzyloksyfenyl)-l-okso-2-hydroksy-2-etoksy-etan, oppløst i 200 ml alkohol, tilsettes 8,2 g 1- (3-amino-3-metyl-butyl)-benzimidazol og omrøres i 3 timer ved 50°C. Derefter avkjøles oppløsningen, tilsettes 4 g natriumborhydrid og omrøres i 6 timer ved romtemperatur. Reaksjonsblandingen opparbeides som beskrevet i eksempel 3. Residuet opp-løses i 200 ml alkohol og surgjøres med 7,2 g oksalsyre, og det utfelte 1-(2-fluor-4-benzyloksyfenyl)-2-[4-(1-benzimidazolyl)-2- metyl-2-butylamino]-etanol-dioksalat (sm.p. 184-188°) avsuges. Fra dioksalatet fremstilles basen (sm.p. 85-88°C) med vandig ammoniakk.
Ved katalytisk hydrogenering av denne forbindelse i
250 ml metanol ved 6 bar trykk med palladiumkull som katalysator ved ca. 30°C, får man 1-(2-fluor-4-hydroksyfenyl)-2-[4-(1-benzimidazolyl)-2-metyl-2-butylamino]-etanol (sm.p. 151-153°C), hvis formiat smelter ved 157-159°C.
Ved tilsetning av den beregnede mengde metansulfonsyre til oppløsningen av basen i etanol får man metansulfonatet,
sm.p. 178-179°C. På tilsvarende måte fremstiller man hydro-kloridet, sm.p. 205°C. Fra basen i vandig acetonitril og den beregnede mengde konsentrert saltsyre, får man dihydroklorid-tetrahydratet, sm.p. 177°C. Analogt får man i vandig etanol sulfat-hydratet, sm.p. 207-208°C.
Til fremgangsmåte 3 Eksempel 7
15,5 g 1-(3-[2-hydroksy-2-(4-benzyloksyfenyl)-benzyletyl-amino]-propyl)-1,2,3,4-tetrahydro-4-kinazolon (sm.p. = 119-121°C) oppløses i 250 ml metanol og debenzyleres ved 60°C, 6 bar trykk under tilsetning av palladium som katalysator. Efter opptagelse av 2 mol hydrogen opparbeides hydrogeneringsproduktet, hvorved man får 8 g 1-(3-[2-hydroksy-2-(4-hydroksyfenyl)-etylamino]-propyl)-1,2,3,4-tetrahydro-4-kinazolon, hvis formiat smelter ved 174-176°C. Utbyttet er 61,^5% av det teoretiske.
Eksempel 8
15 g 2'-benzyloksy-51 -[l-hydroksy-2-[4-(1-imidazolyl)-2-metyl-2-butylamino]-etyl]-acetanilid (sm.p. for dioksalatet 160-163°C), 18,5 g KOH, 80 ml alkohol og 15 ml vann kokes i 24 timer under tilbakeløpskjøling, og derefter isoleres den dannede 1- (3-amino-4-benzyloksyfenyl)-2-[4-(1-imidazolyl)-2-metyl-2-butylamino]-etanol som trioksalat (sm.p. = 95-100°C). Med vandig ammoniakk fremstiller man av dette basen, som man omsetter med kaliumcyanat til 1- (21-benzyloksy-51-[l-hydroksy-2-[4-(1-imidazolyl)-2- metyl-2-butylamino]-etyl]-fenyl)-urinstoff (sm.p. 142-143°C).
Ved katalytisk hydrogenering av 5,1 g av denne forbindelse i 100 ml metanol med palladiumkull som katalysator får man 3,5 g 1-(2'-hydroksy-5'-[l-hydroksy-2-[4-(1-imidazolyl)-2-metyl-2-butyl-amino]-etyl]-fenyl)-urinstoff, hvis sulfat smelter ved 243-244°C. Utbyttet er 70% av det teoretiske.
Eksempel 9
8,5 g 2'-benzyloksy-5'-[l-hydroksy-2-[4-(1-imidazolyl)-2-metyl-4-butylamino]-etyl]-benzoesyremetylester (sm.p. for dioksalatet 156-158°C) hydrogeneres under tilsetning av palladium som katalysator i 100 ml metanol under normalbetingeIser, efter opptagelse av 1 mol hydrogen frafiltreres katalysatoren, og til oppløsningen settes 15 ml monometylamin. Efter 2 dager avdestilleres oppløsningsmidlet, residuet oppløses med 15 ml alkohol og 15 ml vann og surgjøres med 2 g kons. svovelsyre.
Det isoleres 4,5 g 5-[l-hydroksy-2-[4-(1-imidazolyl)-2-metyl-2-butylamino]-etyl]-N-metyl-salicylamid-sulfat med smeltepunkt 263-265°C (spaltn.). Utbyttet utgjør 52% av det teoretiske.
Eksempel 10
13,5 g 2'-benzyloksy-51 -[l-hydroksy-2-[4-(1-imidazolyl)-2-metyl-4-butylamino]-etyl]-benzoesyremetylester (sm.p. for dioksalatet = 156-158°C) reduseres i 200 ml tetrahydrofuran med 6 g litiumaluminiumhydrid til 1-(3-hydroksymetyl-4-benzyloksy-fenyl)-2-[4-(1-imidazolyl)-2-metyl-2-butylamino]-etanol, hvis dioksalat smelter ved 144-146°C. Fra 10 g dioksalat fremstilles med vandig ammoniakk basen, og denne hydrogeneres med palladium som katalysator i 100 ml metanol. Man får 4,5 g 1-(3-hydroksy-metyl-4-hydroksyfenyl)-2- [4- (1-imidazolyl)-2-metyl-2-butylamino]-etanol (sm.p. = 135-137°C), hvis benzoat smelter ved 150-152°C. Utbyttet er 83% av det teoretiske.
Claims (1)
- Analogifremgangsmåte for fremstilling av terapeutiskaktive forbindelser med den generelle formel hvor Het betyrn betyr et helt tall fra 1 til 4; R^ betyr H eller acyl;R2 betyr H, R^, NHS02R?, NHCORg, NHCONHRg, NH-CH^CgH^Rg, CH2OH, CH2S02R?, CONHRg, halogen eller CN; R^ betyr H, halogen, R7 eller OR^,idet R2 og R^ sammen også kan betyR4 betyr H, CH3 eller C E^ }Rc- og Rg, som kan være like eller forskjellige) betyr H eller CH^; R? betyr C^C^alkyl;Rg betyr H eller C^C^alkyl;Rg betyr H, C^-C^ alkyl eller C^-C^ alkoksy som eventuelt er avbrutt av oksygen;R10 betyr H, C^-^ alkyl eller f enyl;<R>ll°^ R12' som ^an være Uke eller forskjellige, betyr H, CH3, Cl eller OCH3;X betyr CR1Q eller N;Z betyr CH2 eller CO,i form av racemater, enantiomerer, diastereomere antipodepar og syreaddisjonssaltene derav,karakterisert ved at a) et aminoketon med den generelle formelhvor R, til Rg, Het og n har de ovenfor angitte betydninger,og hvor det sentrale nitrogenatom og/eller eventuelt fore-liggende fenoliske OH-grupper kan være beskyttet med hydrogenolytisk avspaltbare beskyttelsesgrupper, reduseres i et egnet opp-løsningsmiddel med hydrogen eller hydrogeneringskatalysatorer eller med hydrider som virker reduserende, og eventuelt fjernes ennu tilstedeværende beskyttelsesgrupper hydrogenolytisk efter reduksjonen, eller b) for fremstilling av slike forbindelser med formel I hvor R^ betyr hydrogen, omsettes et amin med den generelle formelhvor R^, Rg, Het og n har de ovenfor angitte betydninger, under betingelsene for reduktiv aminering, med et fenylglyoksal med den generelle formelhvor R^, R2 og R3 har de ovenfor angitte betydninger, og hvor eventuelt tilstedeværende fenoliske OH-grupper også kan være beskyttet ;med;'hydrogenolytisk avspaltbare beskyttelsesgrupper , eventuelt'^i form vav et halvacetal, og eventuelt tilstedeværende beskyttelsesgrupper avspaltes hydrogenolytisk,eller c) fra en forbindelse med den generelle formelhvor R3 til Rg, n og Het har de ovenfor angitte betydninger,og R' betyr H eller en hydrogenolytisk avspaltbar beskyttelsesgruppe, R^' betyr R^ el ler en hydrogenolytisk avspaltbar beskyttelsesgruppe, og R2' betyr R2, idet R^ i denne sammenheng skal erstattes med R^', og minst én av restene R^' og R2<1> betyr en gruppe som skal fjernes, fjernes beskyttelsesgruppen(e),og de i henhold til a) til c) erholdte forbindelser separeres eventuelt i enantiomerene, eventuelt også i de diastereomere antipodepar, og eventuelt overføres erholdte baser til syreaddisjonssalter, erholdte syreaddisjonssalter til de frie baser eller til salter med andre syrer.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19782833140 DE2833140A1 (de) | 1978-07-28 | 1978-07-28 | Neue n-substituierte heterocyclen |
Publications (3)
Publication Number | Publication Date |
---|---|
NO792485L NO792485L (no) | 1980-01-29 |
NO151364B true NO151364B (no) | 1984-12-17 |
NO151364C NO151364C (no) | 1985-03-27 |
Family
ID=6045612
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO792485A NO151364C (no) | 1978-07-28 | 1979-07-27 | Analogifremgangsmaate for fremstilling av terapeutisk aktive n-substituerte heterocykliske forbindelser |
Country Status (20)
Country | Link |
---|---|
US (3) | US4378361A (no) |
EP (1) | EP0008653B2 (no) |
JP (1) | JPS5520783A (no) |
AT (1) | ATE1193T1 (no) |
AU (1) | AU528003B2 (no) |
CA (1) | CA1132550A (no) |
DE (2) | DE2833140A1 (no) |
DK (1) | DK155737C (no) |
ES (3) | ES482898A1 (no) |
FI (1) | FI75562C (no) |
GR (1) | GR69973B (no) |
IE (1) | IE48603B1 (no) |
IL (1) | IL57916A (no) |
MX (1) | MX5654E (no) |
NO (1) | NO151364C (no) |
NZ (1) | NZ191149A (no) |
PH (1) | PH20085A (no) |
PT (1) | PT69991A (no) |
YU (1) | YU42309B (no) |
ZA (1) | ZA793861B (no) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3023369A1 (de) * | 1980-06-23 | 1982-01-14 | Boehringer Mannheim Gmbh, 6800 Mannheim | Aryloxypropanolamine, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
DE3026534A1 (de) * | 1980-07-12 | 1982-03-18 | C.H. Boehringer Sohn, 6507 Ingelheim | 3,1-benzoxazin-2-one, ihre herstellung und verwendung |
US4517310A (en) * | 1981-07-28 | 1985-05-14 | Berlex Laboratories, Inc. | N-[2-hydroxy-2-(3-hydroxyphenyl)ethyl]-1H-benzimidazole-1-butanamine and use thereof as a cardiotonic agent |
FR2523965B1 (fr) * | 1982-03-24 | 1985-09-27 | Bellon Labor Sa Roger | (benzimidazolyl-1)-1, n-((hydroxy-4 methoxy-3 phenyl)-2 hydroxy-2 ethyl) amino-3 butane et ses sels a activite b-adrenergique, leurs applications therapeutiques, et procede pour les preparer |
US4460581A (en) * | 1982-10-12 | 1984-07-17 | Boehringer Ingelheim Kg | (1-Hydroxy-2-amino-alkyl)-substituted benzoxazinones and benzoxazolinones |
ZW6584A1 (en) * | 1983-04-18 | 1985-04-17 | Glaxo Group Ltd | Phenethanolamine derivatives |
DE3325875A1 (de) * | 1983-07-18 | 1985-01-31 | Boehringer Ingelheim KG, 6507 Ingelheim | Neue 1-phenylimidazolidin-2-on-derivate, ihre herstellung und verwendung |
DE3434271A1 (de) * | 1984-09-19 | 1986-03-20 | Beiersdorf Ag, 2000 Hamburg | Substituierte 3,4-dihydro-chinolin-2(1h)-one verfahren zu ihrer herstellung und ihre verwendung sowie diese verbindungen enthaltende zubereitungen |
US4617311A (en) * | 1985-05-17 | 1986-10-14 | Eli Lilly And Company | Antiasthmatic method |
US4626368A (en) * | 1985-12-10 | 1986-12-02 | Mobil Oil Corporation | Benzotriazole derivatives and organic compositions containing same |
GB8609331D0 (en) * | 1986-04-16 | 1986-05-21 | Pfizer Ltd | Anti-arrythmia agents |
US4956382A (en) * | 1987-02-07 | 1990-09-11 | Pfizer Inc. | Sulfonamide anti-arrhythmic agents |
US5003076A (en) * | 1988-10-12 | 1991-03-26 | Shionogi & Co., Ltd. | Benzotriazole derivatives and chiral derivatization reagents for carboxylic acids thereof |
US5104892A (en) * | 1989-12-11 | 1992-04-14 | American Home Products Corporation | Substituted benzimidazole derivatives possessing Class III antiarrhythmic activity |
GB9127304D0 (en) * | 1991-12-23 | 1992-02-19 | Boots Co Plc | Therapeutic agents |
GB9312893D0 (en) * | 1993-06-22 | 1993-08-04 | Boots Co Plc | Therapeutic agents |
US6031109A (en) * | 1993-06-22 | 2000-02-29 | Knoll Aktiengesellschaft | Phenoxy-, phenylthio-, benzoyl-alkyleneaminoalkylene-imidazole derivatives as therapeutic agents |
FR2719587B1 (fr) * | 1994-05-03 | 1996-07-12 | Roussel Uclaf | Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments. |
DK1447400T3 (da) * | 2001-10-25 | 2008-12-08 | Asahi Kasei Pharma Corp | Bicyklisk forbindelse |
US7217724B2 (en) * | 2002-06-12 | 2007-05-15 | Dainippon Sumitomo Pharma Co., Ltd. | Indole, indazole, and benzazole derivative |
US20040127733A1 (en) * | 2002-10-31 | 2004-07-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New beta-agonists, processes for preparing them and their use as pharmaceutical compositions |
DE10251170A1 (de) * | 2002-10-31 | 2004-05-13 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
DE102004001413A1 (de) * | 2004-01-09 | 2005-08-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 3-Hydroxymethyl-4-Hydroxy-Phenyl-Derivate zur Behandlung von chronisch obstruktiver Lungenerkrankung |
CA2552871A1 (en) * | 2004-02-14 | 2005-08-25 | Boehringer Ingelheim International Gmbh | Novel, sustained-action beta-2-agonists and their use as medicaments |
US7405232B2 (en) | 2004-02-14 | 2008-07-29 | Boehringer Ingelheim International Gmbh | Long acting beta-2 agonists and their use as medicaments |
DE102004021779A1 (de) | 2004-04-30 | 2005-11-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
DE102004045648A1 (de) * | 2004-09-21 | 2006-03-23 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Betamimetika zur Behandlung von Atemwegserkrankungen |
DE102005052127A1 (de) | 2005-10-28 | 2007-05-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue indol-haltige Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
DE102005052102A1 (de) * | 2005-10-28 | 2007-05-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
DE102005052101A1 (de) * | 2005-10-28 | 2007-05-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
WO2007093608A1 (de) * | 2006-02-16 | 2007-08-23 | Boehringer Ingelheim International Gmbh | Arzneimittelkombinationen zur behandlung von atemwegserkrankungen |
EP2351742A4 (en) | 2008-10-09 | 2012-03-28 | Asahi Kasei Pharma Corp | indazole |
EP2345644A4 (en) | 2008-10-09 | 2012-03-21 | Asahi Kasei Pharma Corp | INDAZOLE COMPOUND |
US20100222404A1 (en) * | 2008-11-04 | 2010-09-02 | Asahi Kasei Pharma Corporation | Indazole derivative dihydrochloride |
US10955148B2 (en) | 2017-03-16 | 2021-03-23 | Therma-Stor, Llc | Split dehumidification system with secondary evaporator and condenser coils |
US11668476B2 (en) | 2017-03-16 | 2023-06-06 | Therma-Stor LLC | Heat modulation dehumidification system |
US10168058B2 (en) * | 2017-03-16 | 2019-01-01 | Therma-Stor LLC | Dehumidifier with secondary evaporator and condenser coils |
US10921002B2 (en) | 2017-03-16 | 2021-02-16 | Therma-Stor LLC | Dehumidifier with secondary evaporator and condenser coils in a single coil pack |
US11573016B2 (en) | 2017-03-16 | 2023-02-07 | Therma-Stor LLC | Water cooled dehumidification system |
US11573015B2 (en) | 2017-03-16 | 2023-02-07 | Therma-Stor LLC | Split dehumidification system with secondary evaporator and condenser coils |
US10845069B2 (en) * | 2017-03-16 | 2020-11-24 | Therma-Stor LLC | Dehumidifier with multi-circuited evaporator and secondary condenser coils |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE643224C (de) * | 1933-12-23 | 1937-04-05 | Siemens Schuckertwerke Akt Ges | Einrichtung zum Loeschen von Wechselstromunterbrechungslichtboegen |
US3274194A (en) * | 1963-03-29 | 1966-09-20 | Miles Lab | Quinazolinedione derivatives |
GB1200886A (en) * | 1966-09-23 | 1970-08-05 | Allen & Hanburys Ltd | Phenylaminoethanol derivatives |
DE1934037A1 (de) * | 1969-07-04 | 1971-01-07 | Cassella Farbwerke Mainkur Ag | Basisch substituierte Derivate des 2,4-(1H,3H)-Chinazolindions |
GB1301134A (en) * | 1970-07-18 | 1972-12-29 | Pfizer Ltd | SUBSTITUTED 1-PHENYL-2-ALLYLAMINO-ALKANOLS, 1-PHENYL-2-ALLYLAMINO-ALKANES AND alpha-AMINOALKYLPHENYL KETONES |
BE787103A (fr) * | 1971-08-04 | 1973-02-02 | Pfizer | Nouveaux derives de propanolamine et composition pharmaceutiqueles contenant |
DE2609645A1 (de) * | 1976-03-09 | 1977-09-15 | Boehringer Sohn Ingelheim | Aminoalkylheterocyclen |
DE2644833A1 (de) * | 1976-10-05 | 1978-04-20 | Boehringer Sohn Ingelheim | Neue 1-aryloxy-2-hydroxy-3-alkylenaminopropane und verfahren zu ihrer herstellung |
-
1978
- 1978-07-28 DE DE19782833140 patent/DE2833140A1/de active Granted
-
1979
- 1979-07-21 AT AT79102580T patent/ATE1193T1/de not_active IP Right Cessation
- 1979-07-21 EP EP79102580A patent/EP0008653B2/de not_active Expired
- 1979-07-21 DE DE7979102580T patent/DE2963105D1/de not_active Expired
- 1979-07-25 GR GR59690A patent/GR69973B/el unknown
- 1979-07-26 YU YU1831/79A patent/YU42309B/xx unknown
- 1979-07-26 MX MX798253U patent/MX5654E/es unknown
- 1979-07-26 JP JP9554779A patent/JPS5520783A/ja active Granted
- 1979-07-27 PT PT69991A patent/PT69991A/pt not_active IP Right Cessation
- 1979-07-27 IL IL57916A patent/IL57916A/xx unknown
- 1979-07-27 NO NO792485A patent/NO151364C/no unknown
- 1979-07-27 ES ES482898A patent/ES482898A1/es not_active Expired
- 1979-07-27 NZ NZ191149A patent/NZ191149A/xx unknown
- 1979-07-27 ES ES482897A patent/ES482897A1/es not_active Expired
- 1979-07-27 DK DK317679A patent/DK155737C/da not_active IP Right Cessation
- 1979-07-27 ES ES482888A patent/ES482888A1/es not_active Expired
- 1979-07-27 AU AU49303/79A patent/AU528003B2/en not_active Ceased
- 1979-07-27 CA CA332,719A patent/CA1132550A/en not_active Expired
- 1979-07-27 FI FI792356A patent/FI75562C/fi not_active IP Right Cessation
- 1979-07-27 ZA ZA00793861A patent/ZA793861B/xx unknown
- 1979-08-08 IE IE1424/79A patent/IE48603B1/en not_active IP Right Cessation
-
1981
- 1981-07-22 US US06/285,713 patent/US4378361A/en not_active Expired - Fee Related
- 1981-11-16 PH PH26501A patent/PH20085A/en unknown
-
1982
- 1982-11-23 US US06/443,912 patent/US4581367A/en not_active Expired - Fee Related
-
1985
- 1985-12-09 US US06/806,692 patent/US4647563A/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO151364B (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive n-substituerte heterocykliske forbindelser | |
US4460581A (en) | (1-Hydroxy-2-amino-alkyl)-substituted benzoxazinones and benzoxazolinones | |
JP4212117B2 (ja) | 選択的β▲下3▼アドレナリン作動性アゴニスト | |
US4343800A (en) | 1-Aryloxy-2-hydroxy-3[(heterocyclic-substituted alkyl)-amino]propanes and salts thereof | |
CA1329937C (en) | 1-phenyl-3-naphthalenyloxypropanamines | |
US3536713A (en) | N-(hydroxy-cyclohexyl)-aminobenzylamines and the salts thereof | |
EP0775118B1 (en) | Benzimidazole derivatives having dopaminergic activity | |
EP0227241B1 (en) | Medicinal indole and indazole keto sulphone derivatives | |
US4363808A (en) | N-(3-Phenoxy-2-hydroxypropyl)benzimidazole-1-alkanamines | |
EP0049779B1 (en) | 3-aminoindazole derivatives and process for preparation thereof | |
CA1208643A (en) | 1,5-diphenyl-pyrazolin-3-one compounds, process and intermediates for preparation thereof and pharmaceutical compositions containing them | |
FI80024C (fi) | Foerfarande foer framstaellning av heteroaryloxipropanolaminer avsedda till anvaendning vid behandling och foerebyggande av hjaert- och blodomloppssjukdomar. | |
US5274118A (en) | Process for preparing (2R)-methyl-4,4,4-trifluorobutylamine | |
KR840000677B1 (ko) | N-치환된 헤테로 사이클렌의 제조방법 | |
JPS5838237A (ja) | 新規のプロピレン−ジアミン誘導体の製造方法 | |
US4434174A (en) | Treating cardiovascular diseases with N-(3-phenoxy-2-hydroxypropyl)benzimidazole-1-alkanamines | |
DE69609707T2 (de) | Phenoxyethylamin-derivate mit hoher affinität fur den 5-ht1a-rezeptor, verfahren zu ihrer herstellung, ihre verwendung als medikamente und sie enthaltende pharmazeutische zusammensetzungen | |
US4042713A (en) | Pharmaceutical compositions containing a 1-(2-alkyl-3,4-dihydroxy-phenyl)-2-(phenylalkyl-amino)-alkanol-(1) and method of use |